OrbusNeich Medical Group Holdings publishes Annual Report 2025

  • OrbusNeich released annual report for year ended Dec. 31, 2025, citing record revenue driven by stronger demand across US, APAC, EMEA.
  • US market emerged as key growth engine, with sales rising 37% to US$ 21.2 million.
  • Commercial strategy shifted further toward direct sales, including acquisition of Taiwan distributor in March 2025, expansion of direct teams in Netherlands, Belgium.
  • Product pipeline advanced, with Scoreflex QUAD launched in Japan in Q4 2025, FDA submission for Sapphire 3 CTO indication targeted for H1 2026.
  • Manufacturing footprint expanded, with Hangzhou R&D and production site under construction, start of operations expected in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OrbusNeich Medical Group Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260413-12103194), on April 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.